
Merck Expands Respiratory Portfolio With $10B Verona Acquisition
Merck Bolsters Respiratory Portfolio With $10B Verona Acquisition Ahead of Keytruda Patent Cliff In the second-largest biopharma acquisition of 2025, Merck is acquiring Verona Pharma for $10 billion, a strategic move to strengthen its respiratory pipeline and prepare for the…










